FACTORS PREDICTING THE OUTCOME OF BCG (BACILLUS CALMETTE-GUERIN) THERAPY

Volume 32, Number 5 (2022)

Mantas Eidininkas, Šarūnas Simenas, Stasys Auškalnis Abstract Background: Bacillus Calmette-Guerin is currently con­sidered to be the gold standard in conservative treatment for intermediate and high risk non-muscle invasive blad­der cancer (NMIBC). However, up to 40% of the patients, treated with adjuvant BCG therapy, experience failure. As the new methods of treatment after BCG failure ap­pear,…